---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Development, Production, and Commercialization of Ebola Neutralizing Single Monoclonal Antibody for the Treatment of Ebola Virus Disease in Humans"
date: 2026-02-05 19:08:48 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-05235
original_published: 2021-03-15 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Development, Production, and Commercialization of Ebola Neutralizing Single Monoclonal Antibody for the Treatment of Ebola Virus Disease in Humans

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 15, 2021 00:00 UTC
**Document Number:** 2021-05235

## Summary

The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. and European Patents and Patent Applications listed in the Supplementary Information section of this Notice to Ridgeback Biotherapeutics, L.P., located in Miami, Florida.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/03/15/2021-05235/prospective-grant-of-an-exclusive-patent-license-development-production-and-commercialization-of)
- API: https://www.federalregister.gov/api/v1/documents/2021-05235

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
